Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharming Group (PHAR)
NASDAQ:PHAR
Pharming Group (PHAR) Stock Price & Analysis
93 Followers
PHAR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.97 - $16.71
Previous Close$8.51
Volume230.00
Average Volume (3M)4.80K
Market Cap
$565.26M
Enterprise Value$523.07M
Total Cash (Recent Filing)€213.42M
Total Debt (Recent Filing)€171.54M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 01, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding67,107,324
10 Day Avg. Volume7,289
30 Day Avg. Volume4,802
Standard Deviation0.14
R-Squared0.00380
Alpha-0.00627
Financial Highlights & Ratios
Price to Book (P/B)3.31
Price to Sales (P/S)1.99
Price to Cash Flow (P/CF)10.50
P/FCF Ratio9.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.50Price Target Upside352.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Pharming Group News
PremiumCompany Announcements
Pharming Group Delays Leniolisib EU Approval
PremiumCompany Announcements
Pharming Group Shareholders Approve Key Proposals
PremiumCompany Announcements
Pharming Group Announces Convertible Bonds RedemptionPremiumCompany Announcements
Pharming Group Boasts Strong Q1 Revenue Growth
PremiumCompany Announcements
Pharming Group’s Strategic Financial Maneuver
PremiumCompany Announcements
Pharming Group Lauded for Rare Disease TreatmentPremiumCompany Announcements
Pharming Completes Trial Enrollment for Pediatric Drug
Bulls Say, Bears Say
Bulls Say
Financial StrengthThe company ended the quarter financially strong with $203.5 million in cash.
Regulatory ApprovalsJoenja recently received approval from the FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older.
Revenue GrowthTotal revenue guidance for 2024 remains strong, representing 14-20% growth.
Bears Say
EarningsPharming posted EPS of ($0.019) compared to the estimate of $0.014.
Financial PerformanceRuconest revenue increased 8% Year-over-Year, but fell short of the estimate.
Regulatory IssuesThe clock is now stopped due to CHMP requiring completion of manufacturing requests pre-approval.
---
Ownership Overview
0.00%
Insiders
<0.01% Mutual Funds
0.03% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHAR FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $6.97 and its highest was $16.71 in the past 12 months.
What is Pharming Group’s market cap?
Currently, no data Available
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Aug 01, 2024 which is in 7 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on May 08, 2024. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of $0.007 by -$0.197.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is >-$0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 67,835,434 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of -$0.19 in its last earnings report, missing expectations of $0.007. Following the earnings report the stock price went down -1.656%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in PHAR
---
Pharming Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.50 (352.41% Upside)
$38.50 (352.41% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.06%
12-Months-Change
Fundamentals
Return on Equity
-5.12%
Trailing 12-Months
Asset Growth
4.41%
Trailing 12-Months
Company Description
Pharming Group
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. Most of the revenue generated from the United States.
---
PHAR Company Deck
---
PHAR Earnings Call
Q1 2024
0:00 / 0:00
---
PHAR Stock 12 Month Forecast
Average Price Target
$38.50
▲(352.41% Upside)
Technical Analysis
Best Analysts Covering PHAR
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-19.34%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.34% per trade.
---